Squamous Cell Carcinoma of the Esophagus.
Endoscopic eradication therapy
Epidemiology
Esophageal squamous cell carcinoma
Neoadjuvant chemoradiotherapy
Prognosis
Journal
Gastroenterology clinics of North America
ISSN: 1558-1942
Titre abrégé: Gastroenterol Clin North Am
Pays: United States
ID NLM: 8706257
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
entrez:
24
9
2022
pubmed:
25
9
2022
medline:
28
9
2022
Statut:
ppublish
Résumé
Esophageal squamous cell carcinoma (ESCC) is common in the developing world with decreasing incidence in developed countries and carries significant morbidity and mortality. Major risk factors for ESCC development include significant use of alcohol and tobacco. Screening for ESCC can be recommended in high-risk populations living in highly endemic regions. The treatment of ESCC ranges from endoscopic resection therapy or surgery in localized disease to chemoradiotherapy in metastatic disease, and prognosis is directly related to the stage at diagnosis. New immunotherapies and molecular targeted therapies may improve the dismal survival outcomes in patients with metastatic ESCC.
Identifiants
pubmed: 36153105
pii: S0889-8553(22)00031-0
doi: 10.1016/j.gtc.2022.06.005
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
457-484Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure D C. Codipilly: None. K K. Wang: Research funding from PCI, Interscope, Erbe, Pentax Medical Consulting: Ironwood Pharma, GIE Medical